Yao Gang, Wei Xiaochun, Zhong Yu, Liu Guofeng, Zhang Yanzhuo, Chen Yanhua
Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Anesthesiology, Liuzhou Workers' Hospital, Liuzhou, China.
Front Med (Lausanne). 2025 Jun 25;12:1525973. doi: 10.3389/fmed.2025.1525973. eCollection 2025.
This study aimed to evaluate the safety and efficacy of ciprofol for anesthesia induction in elderly patients undergoing lumbar surgery.
Sixty patients aged 65-80 years scheduled for elective lumbar surgery under general anesthesia were randomly divided into two groups ( = 30 each): ciprofol group and propofol group. The ciprofol group received intravenous ciprofol 0.4 mg/kg combined with sufentanil 0.4 μg/kg, while the propofol group received propofol 2 mg/kg combined with sufentanil 0.4 μg/kg for anesthesia induction. Hemodynamic parameters including bispectral index (BIS), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), cardiac index (CI), pulse pressure variation (PPV), systemic vascular resistance index (SVRI), and stroke volume index were recorded during induction. Time to achieve target anesthetic depth was also evaluated. Adverse events including movement, lacrimation, hypotension, hypertension, bradycardia, and coughing during induction were documented.
Both groups showed comparable time to achieve target anesthetic depth and similar trends in hemodynamic changes. However, the ciprofol group demonstrated significantly lower incidence of hypotension compared to the propofol group (20% vs. 63%, < 0.05), with reduced norepinephrine consumption. The incidence of other adverse events showed no significant differences between groups.
Ciprofol demonstrates comparable safety and efficacy to propofol for anesthesia induction in elderly patients undergoing lumbar surgery, with superior hemodynamic stability, supporting its clinical application in geriatric lumbar surgery.
The trial was registered, before patient enrollment, in the Chinese Clinical Trial Registry (www.chictr.org.cn) (Clinical trial number: ChiCTR2300069858, https://www.chictr.org.cn/showproj.html?proj=192839, principal investigator's name: Gang Yao, date of registration: 28/03/2023).
本研究旨在评估环泊酚用于老年腰椎手术患者麻醉诱导的安全性和有效性。
将60例年龄在65 - 80岁、计划在全身麻醉下行择期腰椎手术的患者随机分为两组（每组n = 30）：环泊酚组和丙泊酚组。环泊酚组静脉注射环泊酚0.4 mg/kg联合舒芬太尼0.4 μg/kg，丙泊酚组静脉注射丙泊酚2 mg/kg联合舒芬太尼0.4 μg/kg进行麻醉诱导。诱导过程中记录包括脑电双频指数（BIS）、收缩压（SBP）、舒张压（DBP）、平均动脉压（MAP）、心脏指数（CI）、脉压变异度（PPV）、全身血管阻力指数（SVRI）和每搏量指数在内的血流动力学参数。同时评估达到目标麻醉深度的时间。记录诱导期间的不良事件，包括体动、流泪、低血压、高血压、心动过缓和咳嗽。
两组达到目标麻醉深度的时间相当，血流动力学变化趋势相似。然而，与丙泊酚组相比，环泊酚组低血压发生率显著更低（20% 对63%，P < 0.05），去甲肾上腺素用量减少。其他不良事件的发生率在两组间无显著差异。
在老年腰椎手术患者的麻醉诱导中，环泊酚与丙泊酚的安全性和有效性相当，血流动力学稳定性更佳，支持其在老年腰椎手术中的临床应用。
该试验在患者入组前已在中国临床试验注册中心（www.chictr.org.cn）注册（临床试验注册号：ChiCTR2300069858，https://www.chictr.org.cn/showproj.html?proj = 192839，主要研究者姓名：姚刚，注册日期：2023年3月28日）。
Zotero 插件
